Immunocore Holdings Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Immunocore Holdings kazanç ve gelirin sırasıyla yıllık 5.8% ve 13.9% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 4.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -49.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

5.8%

Kazanç büyüme oranı

4.6%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.3%
Gelir büyüme oranı	13.9%
Gelecekteki özkaynak getirisi	-49.4%
Analist kapsamı	Good
Son güncelleme	19 Nov 2024

Gelecekteki son büyüme güncellemeleri

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11

Recent updates

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Oct 24

Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry

Sep 19

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Aug 12

Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?

Jul 24

Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Jun 16

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

May 11

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Apr 05

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Jan 22

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Jan 21

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Dec 18

Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

May 08

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Nov 16

Immunocore: Attractive Commercial-Stage Biopharma

Oct 05

Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Aug 12

Immunocore GAAP EPS of -$0.17, revenue of $38.92M

Aug 10

Immunocore to raise $140M in private placement financing

Jul 18

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:IMCR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	376	-103	-34	-50	11
12/31/2025	351	-73	-36	-44	15
12/31/2024	311	-44	21	20	15
9/30/2024	296	-47	20	22	N/A
6/30/2024	281	-55	9	11	N/A
3/31/2024	265	-60	-15	-12	N/A
12/31/2023	249	-55	-2	3	N/A
9/30/2023	237	-69	5	10	N/A
6/30/2023	220	-61	6	12	N/A
3/31/2023	201	-52	-6	-1	N/A
12/31/2022	174	-53	-51	-49	N/A
9/30/2022	114	-62	-55	-54	N/A
6/30/2022	82	-112	-96	-94	N/A
3/31/2022	53	-156	-134	-133	N/A
12/31/2021	36	-180	-144	-143	N/A
9/30/2021	37	-150	-137	-135	N/A
6/30/2021	39	-139	-111	-110	N/A
3/31/2021	42	-116	-83	-78	N/A
12/31/2020	41	-101	-88	-84	N/A
9/30/2020	37	-105	-91	-86	N/A
6/30/2020	34	-109	-137	-131	N/A
3/31/2020	33	-120	-146	-141	N/A
12/31/2019	34	-138	-142	-136	N/A
12/31/2018	30	-91	-26	-21	N/A
12/31/2017	19	-66	N/A	-82	N/A
12/31/2016	20	-29	N/A	-45	N/A
12/31/2015	17	20	N/A	-26	N/A
9/30/2014	10	-9	N/A	65	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: IMCR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: IMCR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: IMCR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: IMCR şirketinin gelirinin (yıllık 13.9% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: IMCR şirketinin gelirinin (yıllık 13.9% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: IMCR 3 yıl içinde kârsız olması bekleniyor.

Immunocore Holdings Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates upgraded to US$1.10 loss

Consensus estimates of losses per share improve by 26%

Consensus EPS estimates fall by 26%, revenue upgraded

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Consensus revenue estimates increase by 11%, EPS downgraded

Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023

Recent updates

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to US$1.10 loss

New major risk - Revenue and earnings growth

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry

Immunocore Presents Phase 1 Data of Brenetafusp, an Immtac Bispecific Targeting Prame, in Patients with Ovarian Cancer

Immunocore Holdings plc Announces Brian Di Donato Plans to Leave At the End of the Year as Chief Financial Officer

Consensus estimates of losses per share improve by 26%

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Second quarter 2024 earnings: EPS exceeds analyst expectations

Immunocore Holdings plc to Report Q2, 2024 Results on Aug 08, 2024

Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?

New major risk - Revenue and earnings growth

Immunocore Holdings plc Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma

Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Now 20% undervalued after recent price drop

Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response

Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director

Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma

Now 20% undervalued after recent price drop

Consensus EPS estimates fall by 26%, revenue upgraded

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2024 earnings released: US$0.49 loss per share (vs US$0.43 loss in 1Q 2023)

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Board Member notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunocore Holdings plc to Report Q4, 2023 Results on Feb 28, 2024

Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline

CEO & Director notifies of intention to sell stock

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Head of Research & Development notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus EPS estimates upgraded to UK£0.80 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Head of Research & Development notifies of intention to sell stock

New major risk - Revenue and earnings growth

Head of Research & Development notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus estimates of losses per share improve by 12%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Immunocore Holdings plc to Report Q2, 2023 Results on Aug 10, 2023

CEO & Director notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus EPS estimates fall by 14%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

No longer forecast to breakeven

Consensus EPS estimates fall by 153%, revenue upgraded

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus estimates of losses per share improve by 10%

Immunocore Holdings plc Provides Revenue Guidance for the Fourth Quarter and Twelve Months Ended December 31, 2022

Immunocore Holdings plc Announces the Addition of Three New ImmTAC Product Candidates

Forecast to breakeven in 2025

Consensus forecasts updated

Immunocore Holdings plc Presents Ovarian Cancer Expansion Data for ImmTAC® candidate IMC-C103C targeting MAGE-A4

An unknown buyer acquired a 5% stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Malin Corporation plc (ISE:MLC) for approximately €150 million.

Consensus forecasts updated

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Consensus revenue estimates increase by 27%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors